The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in thai patients

Open AIDS Journal

Volumn 3, Issue , 2009, Pages 38-45

  Nüesch, Reto ^a,b   Gayet Ageron, Angèle ^c   Chetchotisakd, Ploenchan ^d   Prasithsirikul, Wisit ^e   Kiertiburanakul, Sasisopin ^f   Munsakul, Warangkana ^g   Raksakulkarn, Phitsanu ^h   Tansuphasawasdikul, Somboon ⁱ   Chautrakarn, Sineenart ^a   Ruxrungtham, Kiat ^a   Hirschel, Bernard ^c   Anaworanich, Jintanat ^a   Phanuphak, Praphan ^a   Saenawat, Sukontha ^a   Wicharuk, Saijai ^a   Nonenoy, Siriporn ^a   Wannachai, Natnipa ^a   Chuenyam, Theshinee ^a   Nuchapong, Thanthip ^a   Mahanontharit, Apicha ^a   Sankonte, Jongkol ^a   Piyavong, Bucha ^a   Piroj, Vantanit ^a   Seekaow, Napawan ^a   Karakte, Wipawan ^a   Ubolyam, Sasiwimol ^a   Putthwong, Suchittra ^e   Liganonsakul, Sirirat ^e   Sanchiem, Wattana ^e   Boonchoo, Pongpan ^e   Suannum, Malee ^e   Bunyaprawit, Parichat ^d   Kaewmarg, Ratthanant ^d   Penglimoon, Yaowaluk ^h   Khongsawad, Sopha ⁱ   more..

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d KHON KAEN UNIVERSITY   (Thailand)

^e Bamrasnaradura Infectious Disease Institute   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^h Sanpatong Hospital   (Thailand)

ⁱ Buddhachinnaraj Hospital   (Thailand)

Author keywords

HIV infection; Mental health; Quality of life; Treatment interruption

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STRESS; TREATMENT DURATION;

EID: 77953445188     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613600903010038     Document Type: Article

References (50)

1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58(8): 721-728 (Pubitemid 32717795)
2. Atkinson JH, Grant I, Kennedy CJ, et al. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry 1988; 45(9): 859-864 (Pubitemid 18222931)
3. Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24(2): 103-113 (Pubitemid 24253677)
4. Hartzell JD, Janke IE, Weintrob AC. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008; 62(2): 246-255
5. Zinkernagel C, Taffe P, Rickenbach M, et al. Importance of mental health assessment in HIV-infected outpatients. J Acquir Immune Defic Syndr 2001; 28(3): 240-249 (Pubitemid 33055449)
6. Benson CA.Structured treatment interruption in HIV infection. AIDS Read 2001; 11(2): 99-102. (Pubitemid 32172759)
7. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect Dis 2001; 1(1): 53-59
8. Lori F, Maserati R, Foli A, et al. Structured treatment interruptions to control HIV-1 infection. Lancet 2000; 355(9200): 287-288 (Pubitemid 30068525)
9. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38(2): 174-179 (Pubitemid 40189324)
10. Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4- guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39(5): 523-529 (Pubitemid 41098465)
11. Colette JS, Sabin CA, Lampe FC, et al. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther 2005; 10(3): 459-467
12. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993-2003.
13. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-1193
14. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355(22): 2283-2296 (Pubitemid 44837777)
15. Ananworanich J, Hirschel B. Intermittent therapy for the treatment of chronic HIV infection. AIDS 2007; 21(2): 123-134 (Pubitemid 46036919)
16. Nüesch R, Hirschel B. Treatment interruption for convenience, cost cutting and toxicity sparing. Curr Opin HIV AIDS 2007; 2: 31-38. (Pubitemid 46941139)
17. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368(9534): 459-465 (Pubitemid 44142768)
18. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17(15): F33-37. (Pubitemid 37338886)
19. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6(6): 481-493 (Pubitemid 27431704)
20. Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed). 1986; 292(6516): 344.
21. Lovibond SH, Lovibond PF. Depression anxiety stress scale. 2008. Available from: http://www2.psy.unsw.edu.au/groups/dass/.
22. Wu AW. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS 2000; 14(10): 1449-1451
23. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997; 6(6): 531-554 (Pubitemid 27431708)
24. Ichikawa M, Natpratan C. Quality of life among people living with HIV/AIDS in northern Thailand: MOS-HIV Health Survey. Qual Life Res 2004; 13(3): 601-610 (Pubitemid 38526535)
25. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40(4): 594-600. (Pubitemid 40270231)
26. Burgess A, Dayer M, Catalan J, Hawkins D, Gazzard B. The reliability and validity of two HIV-specific health-related Quality-of- Life measures: a preliminary analysis. AIDS 1993; 7(7): 1001-1008 (Pubitemid 23239676)
27. Carretero MD, Burgess AP, Soler P, Soler M, Catalan J. Reliability and validity of an HIV-specific health-related quality-of-life measure for use with injecting drug users. AIDS 1996; 10(14): 1699-1705 (Pubitemid 26394989)
28. Cronbach L. Coefficient alpha and the internal structure of test. Psychometrika 1951; 16: 297-334.
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-370
30. Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess 1998; 71(3): 349-367 (Pubitemid 29066373)
31. Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther 1997; 35(1): 79-89. (Pubitemid 27026171)
32. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-860
33. Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS 2008; 22(7): 577-585 (Pubitemid 352040052)
34. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-daysoff (FOTO) study. HIV Clin Trials 2007; 8(1): p. 19-23.
35. Ruiz L, Paredes R, Gómez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21(2): 169-178 (Pubitemid 46036924)
36. Marchou B, Tangre P, Charreau I, et al. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 2007; 21(4): 457-466 (Pubitemid 46263256)
37. Maserati R, Foli A, Tomasoni L, et al. Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. Curr HIV Res 2007; 5(3): 337-343 (Pubitemid 46785069)
38. Palmisano L, Giuliano M, Bucciardini R, et al. Determinants of virologic and immunologic outcomes in chronically HIV-Infected subjects undergoing repeated treatment interruptions: the istituto superiore di sanita-pulsed antiretroviral therapy (ISS-PART) study. J Acquir Immune Defic Syndr 2007; 46(1): 39-47. (Pubitemid 47507432)
39. Burman W, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr 2007; 25: 25. (Pubitemid 351172185)
40. Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007; 8(5): 320-327 (Pubitemid 350103429)
41. Deyo RA, Carter WB. Strategies for improving and expanding the application of health status measures in clinical settings. A researcher-developer viewpoint. Med Care 1992; 30(5 Suppl): MS176-186; discussion MS196-209.
42. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169(1): 28-36. (Pubitemid 24976889)
43. Thavichachart N, Intoh P, Thavichachart T, et al. Epidemiological survey of mental disorders and knowledge attitude practice upon mental health among people in Bangkok Metropolis. J Med Assoc Thai 2001; 84(Suppl 1): S118-26. (Pubitemid 33714843)
44. Lima VD, Geller J, Bangsberg D R, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21(9): 1175-1183 (Pubitemid 46763288)
45. Alciati A, Starace F, Scaramelli B, et al. Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? Eur Psychiatry 2001; 16(8): 491-496
46. Rabkin, JG, Ferrando SJ, Lin SH, Sewell M, McElhiney M. Psychological effects of HAART: a 2-year study. Psychosom Med 2000; 62(3): 413-422 (Pubitemid 30347085)
47. Poupard M, Ngom Gueye N F, Thiam D, et al. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. HIV Med 2007; 8(2): 92-95 (Pubitemid 46390845)
48. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45(5): 394-402. (Pubitemid 39166911)
49. Starace F, Bartoli L, Aloisi MS, et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002; 106(1): 20-26
50. Scaravilli F, Bazille C, Gray F. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol 2007; 17(2): 197-208. (Pubitemid 46466132)